Allecra Therapeutics, a Lorrach, Germany and Saint Louis, France-based biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, closed a €22M Series B funding round.
The round was led by new investor Delos Capital with participation from existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures and Allecra’s co-Founder Nicholas Benedict.
The company intends to use the funds for Phase 2 development of AAI202, its proprietary, novel antibiotic combination designed to treat drug-resistant Gram-negative bacterial infections.
Led by Nicholas Benedict, CEO, Allecra is a biopharmaceutical company focused on the development of novel treatments to combat multi drug-resistant Gram-negative bacterial infections. Its AAI202 is a combination of a β-lactam antibiotic along with a proprietary, novel Extended Spectrum β-Lactamase Inhibitor, designed for use as broad-spectrum antibacterial therapy to treat hospitalized patients who contract infections caused by Gram-negative bacteria proven or suspected to express certain resistance mechanisms, particularly extended-spectrum β-lactamases (ESBLs).